MX2019003649A - Inhibidores selectivos de jak1 novedosos y usos de los mismos. - Google Patents
Inhibidores selectivos de jak1 novedosos y usos de los mismos.Info
- Publication number
- MX2019003649A MX2019003649A MX2019003649A MX2019003649A MX2019003649A MX 2019003649 A MX2019003649 A MX 2019003649A MX 2019003649 A MX2019003649 A MX 2019003649A MX 2019003649 A MX2019003649 A MX 2019003649A MX 2019003649 A MX2019003649 A MX 2019003649A
- Authority
- MX
- Mexico
- Prior art keywords
- novelty
- disorders
- selective inhibitors
- jak1
- jak1 selective
- Prior art date
Links
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- HGNXHCJAXKQSOQ-UHFFFAOYSA-N 12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,3,6,8,10-pentaene Chemical class N1C=NC=2C1=C1C(=NC=2)C=CO1 HGNXHCJAXKQSOQ-UHFFFAOYSA-N 0.000 abstract 1
- 102000002295 Janus Kinase 1 Human genes 0.000 abstract 1
- 108010000837 Janus Kinase 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Abstract
Los nuevos derivados de 1H-furo[3,2-b]imidazo[4,5-d]piridina son inhibidores de cinasa Jak1 selectivos útiles en tratar trastornos relacionados a actividades de Jak1 tales como enfermedades o trastornos autoinmunes, enfermedades o trastornos inflamatorios y cáncer o enfermedades o trastornos neoplásicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403660P | 2016-10-03 | 2016-10-03 | |
| PCT/US2017/054668 WO2018067422A1 (en) | 2016-10-03 | 2017-09-30 | Novel jak1 selective inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003649A true MX2019003649A (es) | 2019-08-14 |
| MX390005B MX390005B (es) | 2025-03-20 |
Family
ID=61831161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003649A MX390005B (es) | 2016-10-03 | 2017-09-30 | Inhibidores selectivos de jak1 novedosos y usos de los mismos. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10738060B2 (es) |
| EP (1) | EP3509591B1 (es) |
| JP (1) | JP7089141B2 (es) |
| KR (1) | KR102399848B1 (es) |
| CN (2) | CN113214278B (es) |
| AU (3) | AU2017339417C1 (es) |
| DK (1) | DK3509591T3 (es) |
| EA (1) | EA201990523A1 (es) |
| ES (1) | ES2901216T3 (es) |
| HK (1) | HK1253040A1 (es) |
| HR (1) | HRP20211965T1 (es) |
| HU (1) | HUE058120T2 (es) |
| IL (3) | IL265358B (es) |
| MX (1) | MX390005B (es) |
| NZ (1) | NZ751284A (es) |
| PL (1) | PL3509591T3 (es) |
| PT (1) | PT3509591T (es) |
| RS (1) | RS62695B1 (es) |
| WO (1) | WO2018067422A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113214278B (zh) | 2016-10-03 | 2022-10-28 | 杭州高光制药有限公司 | 新型Jak1选择性抑制剂及其用途 |
| AU2018208516B2 (en) | 2017-01-11 | 2021-07-08 | Aqilion Ab | Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof |
| SG11202104321PA (en) | 2018-10-31 | 2021-05-28 | Incyte Corp | Combination therapy for treatment of hematological diseases |
| EA202192426A1 (ru) * | 2019-03-05 | 2021-11-15 | Инсайт Корпорейшн | Ингибиторы путей jak1 для лечения хронической дисфункции аллотрансплантата легких |
| TW202102222A (zh) * | 2019-03-19 | 2021-01-16 | 美商英塞特公司 | 白斑病之生物標記物 |
| EP4248967A3 (en) * | 2019-06-06 | 2023-10-11 | Hangzhou Highlightll Pharmaceutical Co., Ltd. | Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof |
| IL318796A (en) * | 2019-06-06 | 2025-04-01 | Hangzhou Highlightll Pharmaceutical Co Ltd | Method for preparing a furoimidazopyridine compound, polymorph and salt polymorph |
| BR112022023550A2 (pt) | 2020-05-19 | 2023-01-03 | Bayer Cropscience Ag | (tio)amidas azabicíclicas como compostos fungicidas |
| BR112022024413A2 (pt) | 2020-06-10 | 2023-02-07 | Bayer Ag | Heterociclos substituídos com azabiciclila como fungicidas inovadores |
| EP4351584A4 (en) * | 2021-06-07 | 2025-04-23 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE |
| WO2023035913A1 (en) * | 2021-09-13 | 2023-03-16 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Methods of treating cns disorders |
| CN114213424B (zh) * | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
| WO2025224600A1 (en) * | 2024-04-21 | 2025-10-30 | Biohaven Therapeutics Ltd. | Treatment of alpha-synucleinopathies and neuroprotection |
| WO2025248468A1 (en) | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria) |
| WO2026002028A1 (zh) * | 2024-06-26 | 2026-01-02 | 杭州多域生物技术有限公司 | 稠杂芳环类化合物、其药物组合物及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| CN1163223C (zh) | 1998-07-28 | 2004-08-25 | 田边制药株式会社 | 肠内目标部位释放型制剂 |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| US20070185152A1 (en) * | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| CN101316853B (zh) * | 2005-08-04 | 2014-09-24 | 西特里斯药业公司 | 作为sirtuin调节剂的苯并噻唑和噻唑并吡啶 |
| EP2483272A4 (en) * | 2009-09-29 | 2013-09-18 | Xcovery Holding Co Llc | SELECTIVE PI3K (DELTA) INHIBITOR |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| BR112013008240A2 (pt) | 2010-10-08 | 2017-12-12 | Abbvie Inc | compostos de furo [3-2-d] pirimidina |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| IN2014MN00228A (es) | 2011-08-12 | 2015-09-25 | Nissan Chemical Ind Ltd | |
| SG11201503141TA (en) * | 2012-11-01 | 2015-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
| WO2015061665A1 (en) | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| BR112016025427A2 (pt) * | 2014-04-30 | 2017-08-15 | Incyte Corp | processos de preparação de um inibidor de jak1 e formas do mesmo |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| CN113214278B (zh) | 2016-10-03 | 2022-10-28 | 杭州高光制药有限公司 | 新型Jak1选择性抑制剂及其用途 |
-
2017
- 2017-09-30 CN CN202110514751.5A patent/CN113214278B/zh active Active
- 2017-09-30 US US16/333,994 patent/US10738060B2/en not_active Ceased
- 2017-09-30 PL PL17858944T patent/PL3509591T3/pl unknown
- 2017-09-30 EA EA201990523A patent/EA201990523A1/ru unknown
- 2017-09-30 HU HUE17858944A patent/HUE058120T2/hu unknown
- 2017-09-30 WO PCT/US2017/054668 patent/WO2018067422A1/en not_active Ceased
- 2017-09-30 DK DK17858944.6T patent/DK3509591T3/da active
- 2017-09-30 EP EP17858944.6A patent/EP3509591B1/en active Active
- 2017-09-30 AU AU2017339417A patent/AU2017339417C1/en active Active
- 2017-09-30 RS RS20211521A patent/RS62695B1/sr unknown
- 2017-09-30 CN CN201780004442.5A patent/CN108366994B/zh active Active
- 2017-09-30 KR KR1020197009016A patent/KR102399848B1/ko active Active
- 2017-09-30 NZ NZ751284A patent/NZ751284A/en unknown
- 2017-09-30 HK HK18112420.5A patent/HK1253040A1/zh unknown
- 2017-09-30 PT PT178589446T patent/PT3509591T/pt unknown
- 2017-09-30 ES ES17858944T patent/ES2901216T3/es active Active
- 2017-09-30 JP JP2019517991A patent/JP7089141B2/ja active Active
- 2017-09-30 MX MX2019003649A patent/MX390005B/es unknown
- 2017-09-30 HR HRP20211965TT patent/HRP20211965T1/hr unknown
- 2017-09-30 US US17/526,799 patent/USRE49834E1/en active Active
-
2019
- 2019-03-13 IL IL265358A patent/IL265358B/en unknown
-
2022
- 2022-02-17 AU AU2022201058A patent/AU2022201058B2/en active Active
- 2022-02-17 AU AU2022201061A patent/AU2022201061B2/en active Active
- 2022-03-10 IL IL291267A patent/IL291267B2/en unknown
- 2022-03-10 IL IL291265A patent/IL291265B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003649A (es) | Inhibidores selectivos de jak1 novedosos y usos de los mismos. | |
| MX2019004070A (es) | Sistema de extraccion de un sistema de circuito cerrado. | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| CR20160449A (es) | Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos | |
| CO2017000586A2 (es) | Formulación en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida | |
| CO2018013803A2 (es) | 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1 | |
| MX388140B (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| MX373586B (es) | Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas. | |
| HUE064667T2 (hu) | Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra | |
| TW201613925A (en) | Imidazopyrazines as LSD1 inhibitors | |
| UY36265A (es) | “derivados de pirrolo[2,3-d]pirimidina”. | |
| CR20160542A (es) | 1 H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS YPIRAZOLO[3,4-c]PlRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEINAS BET | |
| HUE059274T2 (hu) | Imidazo[4,5-d]pirrolo[2,3-b]piridin-származékok mint janus-kinázok inhibitorai | |
| CY1120415T1 (el) | Θεραπευτικα δραστικα παραγωγα πυραζολο-πυριμιδινης | |
| PH12016501232A1 (en) | Pyrazolo[1,5-a]pyridine derivatives and methods of their use | |
| SG11201907095UA (en) | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | |
| MX2016016583A (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| BR112016029630A2 (pt) | derivados heteroaromáticos bicíclicos fundidos como inibidores de inibidores de cinase | |
| UY35625A (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa | |
| CL2019001669A1 (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1. | |
| MX375318B (es) | Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina.. | |
| EA201891349A1 (ru) | Производные гексагидропиразинотриазинона в качестве ингибиторов киназы | |
| WO2014153464A3 (en) | 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer | |
| UA114825C2 (uk) | Терапевтично активні похідні піразолопіримідину | |
| MA47070A (fr) | Pyrazolo[3,4-b]pyridines et imidazo[1,5-b]pyridazines utilisés en tant qu'inhibiteurs de pde1 |